Myeongmun Pharmaceutical Rises 5.36% Amid COVID-19 (Nafamostat) Theme Uptrend

On the 8th, the COVID-19 (Nafamostat) theme showed a strong performance, rising 3.28% compared to the previous day, while Myungmoon Pharmaceutical, a related stock drawing attention, surged 5.36% compared to the previous day. Myungmoon Pharmaceutical is known as a comprehensive pharmaceutical company focusing on prescription drugs.

[Graph] Major stock price changes in the COVID-19 (Nafamostat) theme

According to the analysis by Thinkpool Robo Algorithm RASSI, Myungmoon Pharmaceutical’s quant financial score is 7.3 points, which is lower in stability, profitability, and growth compared to the average of other stocks related to COVID-19 (Nafamostat). This can be interpreted as Myungmoon Pharmaceutical having relatively low investment attractiveness from a financial perspective compared to other stocks. On the other hand, Chong Kun Dang Holdings ranked first in quant financial ranking with higher growth, stability, and profitability scores compared to the average of other stocks.

[Table] Top stocks by financial score within the theme

※ The quant financial score is the result of the Robo Algorithm’s analysis based on each company’s sales growth rate, equity growth rate, debt ratio, current ratio, ROA, ROE, and other factors.

※ This article was generated in real time by an article automatic generation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.

This content was produced with the assistance of AI translation services.